newsfilter
← Latest News
Business Wire·

bioAffinity Technologies Announces Closing of $3.2 Million Offering

BIAFBIAFW
  • bioAffinity Technologies, Inc. closed a public offering of securities for aggregate gross proceeds of $3.2 million before fees & expenses.
  • The offering consisted of 4,000,000 shares of common stock or pre-funded warrants sold at $0.80 per share or $0.793 per pre-funded warrant.
  • Each pre-funded warrant is immediately exercisable for one share of common stock & expires when fully exercised.
  • The closing is expected to occur on or about June 18, 2026, subject to customary conditions.
  • WallachBeth Capital, LLC acted as the sole placement agent for the offering.
  • The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-296764) declared effective by the SEC.
  • CyPath® Lung is a noninvasive Laboratory Developed Test (LDT) using flow cytometry & AI to detect early-stage lung cancer in high-risk patients.
  • Clinical trial results for CyPath® Lung showed 92% sensitivity, 87% specificity, 88% accuracy, & 99% negative predictive value for patients with small indeterminate lung nodules.
  • The test incorporates a fluorescent porphyrin preferentially taken up by cancer cells to identify malignancy in patient sputum.
  • CyPath® Lung is marketed by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies, & operates under CLIA regulations.
  • Forward-looking statements in the release are subject to risks that could cause actual results to differ materially from expectations.